EDGEWISE THERAPEUTICS INC (EWTX)
Health Care · Rare muscle disease therapeutics · NASDAQ
Edgewise Therapeutics develops precision small-molecule muscle modulators targeting rare neuromuscular and cardiac diseases, with sevasemten advancing in late-stage trials for Duchenne and Becker muscular dystrophies.
What EDGEWISE THERAPEUTICS INC does
Edgewise Therapeutics is a late-stage clinical biopharmaceutical company focused on discovering and developing innovative treatments for severe muscle diseases using a proprietary, muscle-focused drug discovery platform. The company leverages custom-built high-throughput systems measuring integrated muscle function to identify small molecule precision medicines regulating key proteins in muscle tissue. Its pipeline centers on sevasemten, a selective fast myosin inhibitor for dystrophinopathies (Duchenne and Becker muscular dystrophies), and cardiac sarcomere modulators EDG-7500 and EDG-15400 for hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
Themes: ["Duchenne muscular dystrophy (DMD) / Becker muscular dystrophy (BMD)","Rare neuromuscular diseases","Hypertrophic cardiomyopathy (HCM)","Heart failure with preserved ejection fraction (HFpEF)","Cardiac muscle disease","Precision medicine / muscle-focused therapeutics","Sarcomere biology","Cardiometabolic disease"]
Fundamentals
- Price$48.35 as of 2026-07-09 close
- Market cap$5.2B as of 2026-07-10
- 1-year return+255.6% as of 2026-07-09 close
- ROE-32.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.29 as of 2026-07-10
Key risks (from latest filing)
["Sevasemten has not yet received FDA approval; failure to meet primary endpoints in ongoing pivotal and Phase 2 trials would substantially delay or prevent commercialization of the company's lead program and primary near-term revenue driver.","The company has incurred significant operating losses ($49.0 million in Q1 2026) with an accumulated deficit of $595.4 million, and while existing cash of $499.6 million is projected to fund operations through at least the next 12 months, long-term funding will depend on clinical success and potential future capital raises.","Macroeconomic and geopolitical developments including inflation, financial sector instability, supply chain disruptions, and potential changes in government policy could impact clinical development timelines, regulatory pathways, and access to capital markets."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.